United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

esteve pharmaceuticals ltd - triamcinolone hexacetonide - suspension for injection - 20mg/1ml

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - hepatitis b surface antigen, recominant - suspension for injection in pre-filled syringe - 20/1 microgram(s)/millilitre - hepatitis vaccines; hepatitis b, purified antigen

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 150 mg/ml - injection, suspension - excipient ingredients: propyl hydroxybenzoate; methyl hydroxybenzoate; water for injections; sodium chloride; macrogol 3350; polysorbate 80 - carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contra- indicated or has been unsuccessful. contraception (ovulation suppression): for long-term prevention of pregnancy in women when administered at 3-month intervals. since loss of bone mineral density (bmd) may occur in pre-menopausal women who use depo-provera long-term (greater than 2 years), women should be assessed, before starting treatment for contraception or endometriosis, regarding the risk of osteoporosis. women under the age of 18 years may be at risk of failing to achieve their predicted peak bone mineral density (see warnings). the 50 mg/1ml vial is not approved for the indication of contraception (ovulation suppression). the injection, depo-provera 150 mg/1ml, should be used for contraception.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - morphine sulfate pentahydrate, quantity: 10 mg/ml - injection, suspension - excipient ingredients: dioleoylphosphatidylcholine; dipalmitoylphosphatidylglycerol; cholesterol; triolein; tricaprylin; sodium chloride; dilute hydrochloric acid; water for injections - for the relief of post-operative pain following major orthopaedic, abdominal, or pelvic surgery via the lumbar epidural route at a maximum recommended dose of 10 mg. appropriate monitoring must be maintained for at least 48 hours - see precautions.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - medroxyprogesterone acetate - suspension for injection - 150mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - triamcinolone acetonide - suspension for injection - 10mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - methylprednisolone acetate - suspension for injection - 40mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

atnahs pharma uk ltd - tetracosactide acetate - suspension for injection - 1mg/1ml

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - bacillus calmette-guerin 3e+006 vu/ml - 6e+006 vu/ml (300,000-600,000 v.u per 0.1 ml suspension) - suspension for injection - active: bacillus calmette-guerin 3e+006 vu/ml - 6e+006 vu/ml (300,000-600,000 v.u per 0.1 ml suspension) excipient: calcium chlorine glucose monohydrate polygeline potassium sodium sodium chloride

Ireland - English - HPRA (Health Products Regulatory Authority)

merck sharp & dohme ireland (human health) limited - strain cr 326f hepatitis a virus, inactivated 50 u - suspension for injection in pre-filled syringe - 50 u/1 millilitre(s) - hepatitis vaccines; hepatitis a, inactivated, whole virus